login
login
Image header Agence Europe
Europe Daily Bulletin No. 12956
Contents Publication in full By article 23 / 40
EU RESPONSE TO COVID-19 / Health

EMA begins formal evaluation of Valneva’s SARS-CoV-2 vaccine and is considering authorisation of Pfizer-BioNTech booster dose for children

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) began, on Wednesday 18 May, the formal scientific evaluation phase of the SARS-CoV vaccine developed by the firm Valneva, VLA200. The company was able to apply for a conditional marketing authorisation for its vaccine for adults aged 18 to 55.

This inactivated, adjuvanted whole virus Covid-19 vaccine, developed by Valneva, has been undergoing a progressive evaluation since 2 December 2021 (see EUROPE...

Contents

Russian invasion of Ukraine
EUROPEAN PARLIAMENT PLENARY
SECTORAL POLICIES
EU RESPONSE TO COVID-19
SOCIAL AFFAIRS - EMPLOYMENT
EXTERNAL ACTION
ECONOMY - FINANCE - BUSINESS
BREACHES OF EU LAW
NEWS BRIEFS